Your session is about to expire
← Back to Search
Immune Checkpoint Inhibitors + Propranolol Hydrochloride for Urothelial Carcinoma
This trial studies the effect of propranolol hydrochloride and pembrolizumab in treating patients with urothelial cancer that has come back or has spread to other places in the body.
- Renal Pelvis Cancer
- Urethral Cancer
- Ureter Cancer
- Urothelial Carcinoma
- Bladder Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2021 Phase 3 trial • 453 Patients • NCT03066778
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You have received chemotherapy or radiotherapy in the past 4 weeks or have not fully recovered from side effects of previous treatments.You have had allergic reactions to similar medications in the past.The study doctor decides that you should not take the study drug.You have a health problem that is not under control, such as a bad infection, heart issues, or mental health concerns that could make it hard for you to follow the study rules.You have had a serious heart condition within the last 3 months before starting the study treatment.You cannot take beta blockers for medical reasons.You are currently taking a specific type of medication called a beta blocker and cannot switch to a different type of medication.You are able to perform daily activities with some difficulty, but it does not greatly affect your ability to function.You have been diagnosed with urothelial carcinoma and are planning to be treated with specific FDA-approved drugs like Pembrolizumab, Avelumab, or Nivolumab.You are expected to live for at least 12 more weeks.
- Group 1: Treatment (propranolol hydrochloride, immune checkpoint inhibitor)
- Group 2: Treatment (immune checkpoint inhibitor)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any precedents for the use of Pembrolizumab in clinical trials?
"Currently, a thousand clinical trials are being conducted to assess the efficacy of Pembrolizumab. Of these studies, 127 have progressed to Phase 3. While most of these research initiatives are located in Melbourne, Victoria; there is an expansive global network running tests with this drug - 35804 sites in total."
Are there vacancies available for participants of this trial?
"Yes, according to information on clinicaltrials.gov the study is still open for enrollment and was initially published on May 20th 2021. The most recent update occurred on June 8th 2022 and 25 people are being recruited from a single medical facility."
For what medical ailments is Pembrolizumab regularly prescribed?
"Pembrolizumab is frequently employed to treat malignant neoplasms, but it can also be a beneficial treatment for unresectable melanoma, microsatellite instability high, and adrenergic alpha-antagonists."
How many participants are included in this clinical experiment?
"Indeed, clinicaltrials.gov reflects that this study is currently enrolling volunteers. It was first posted on May 20th 2021 and has been recently revised as of June 8th 2022. 25 individuals are being sought out from a single site."
What is the Food and Drug Administration's stance on Pembrolizumab?
"Our team at Power has rated the safety of Pembrolizumab a 2 due to its clinical trial phase. This medication is in Phase 2, indicating that while there are some studies backing up its security and tolerability, efficacy data still needs to be collected."
Share this study with friends